Jennifer A. Fox's most recent trade in Apogee Therapeutics Inc. was a trade of 14,461 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 14,461 | 14,461 | - | - | Stock Option (Right to Buy) | |
| Zenas Biopharma Inc | Jennifer A. Fox | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| ProKidney Corp Ordinary | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 125,862 | 125,862 | - | - | Director stock option (right to buy) | |
| ProKidney Corp Ordinary | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 9,535 | 9,535 | - | - | Director stock option (right to buy) | |
| Apogee Therapeutics Inc | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 10,370 | 10,370 | - | - | Stock Option (Right to Buy) | |
| ProKidney Corp Ordinary | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 62,558 | 62,558 | - | - | Director stock option (right to buy) | |
| ProKidney Corp Ordinary | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 46,632 | 46,632 | - | - | Director stock option (right to buy) | |
| ProKidney Corp Ordinary | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 42,515 | 42,515 | - | - | Director stock option (right to buy) | |
| Nuvation Bio Inc Ordinary | Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| ProKidney Corp Ordinary | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2022 | 129,370 | 129,370 | - | - | Stock option (right to buy) | |
| Nuvation Bio Inc Ordinary | Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2022 | 480,000 | 480,000 | - | - | Stock Option (Right to Buy) | |
| Nuvation Bio Inc Ordinary | Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) |